These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 32090065)
1. Herbal Active Ingredients: An Emerging Potential for the Prevention and Treatment of Papillary Thyroid Carcinoma. Yang Y; Chen Q; Yu WY; Zhang HH; Zhong YS; Zhang SZ; Wang JF; Yu CH Biomed Res Int; 2020; 2020():1340153. PubMed ID: 32090065 [TBL] [Abstract][Full Text] [Related]
2. Antitumor Effect of Various Phytochemicals on Diverse Types of Thyroid Cancers. Shin HJ; Hwang KA; Choi KC Nutrients; 2019 Jan; 11(1):. PubMed ID: 30634497 [TBL] [Abstract][Full Text] [Related]
3. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Jeong WJ; Mo JH; Park MW; Choi IJ; An SY; Jeon EH; Ahn SH Cancer Biol Ther; 2011 Sep; 12(5):458-65. PubMed ID: 21725210 [TBL] [Abstract][Full Text] [Related]
4. High iodine effects on the proliferation, apoptosis, and migration of papillary thyroid carcinoma cells as a result of autophagy induced by BRAF kinase. Zhang D; Xu X; Li J; Yang X; Sun J; Wu Y; Qiao H Biomed Pharmacother; 2019 Dec; 120():109476. PubMed ID: 31563816 [TBL] [Abstract][Full Text] [Related]
5. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651 [TBL] [Abstract][Full Text] [Related]
6. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. Tang KT; Lee CH J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995 [TBL] [Abstract][Full Text] [Related]
7. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337 [TBL] [Abstract][Full Text] [Related]
8. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322 [TBL] [Abstract][Full Text] [Related]
9. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF Poyrazoğlu Ş; Bundak R; Baş F; Yeğen G; Şanlı Y; Darendeliler F J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):185-193. PubMed ID: 28077340 [TBL] [Abstract][Full Text] [Related]
11. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer. Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897 [TBL] [Abstract][Full Text] [Related]
12. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma. Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445 [TBL] [Abstract][Full Text] [Related]
13. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area. Kim HJ; Park HK; Byun DW; Suh K; Yoo MH; Min YK; Kim SW; Chung JH Eur J Nutr; 2018 Mar; 57(2):809-815. PubMed ID: 28258306 [TBL] [Abstract][Full Text] [Related]
14. Clinical Analysis of BRAF Dong SY; Chen J; Xia EJ; Lin RX; Du HY; Wang OC; Zhang XH; Hao RT Am Surg; 2020 May; 86(5):450-457. PubMed ID: 32684022 [TBL] [Abstract][Full Text] [Related]
15. BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer. Liu Z; Lv T; Xie C; Di Z Am J Med Sci; 2018 Aug; 356(2):130-134. PubMed ID: 30219154 [TBL] [Abstract][Full Text] [Related]
16. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882 [TBL] [Abstract][Full Text] [Related]
17. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy. Li J; Liang J; Zhao T; Lin Y Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618 [TBL] [Abstract][Full Text] [Related]
18. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study. Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698 [TBL] [Abstract][Full Text] [Related]